We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Lynch syndrome is an inherited condition that increases the risk of several cancers, including colorectal and endometrial. Learn about its symptoms, causes, diagnosis, and management strategies.
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is an inherited genetic condition that significantly increases a person's risk of developing several types of cancer. It is the most common cause of hereditary colorectal cancer, accounting for about 3% to 5% of all colorectal cancer cases. However, it also raises the risk for other cancers, including endometrial (uterine), ovarian, stomach, small intestine, urinary tract, and brain cancers, as well as sebaceous gland adenomas and keratoacanthomas. The syndrome is caused by mutations in one of several DNA mismatch repair (MMR) genes. These genes are crucial for repairing errors that occur when DNA is copied. When these genes are mutated, DNA errors accumulate, leading to an increased risk of cancer.
The journey to understanding Lynch syndrome can be a long and complex one, as illustrated by personal experiences. For some, a diagnosis comes years after surviving cancer, twice. The initial discovery of cancer might be accidental, found during a routine examination when a doctor feels a mass. This was the case for one individual who, in her mid-40s, was completely unaware of any health issues until her OB-GYN detected a mass the size of an orange during a routine check-up. This led to the diagnosis of endometrial and ovarian cancers.
Years later, after surviving these cancers and entering remission, a genetic test revealed a mutation in the MSH6 gene. This mutation is associated with Lynch syndrome. The individual was surprised, having undergone genetic testing 15 years prior and being told she did not have Lynch syndrome. This highlights how scientific understanding and genetic testing capabilities evolve over time, with new gene mutations for Lynch syndrome being discovered.
Lynch syndrome dramatically increases the lifetime risk of developing certain cancers compared to the general population. For example, the lifetime risk of developing colon cancer for individuals with Lynch syndrome can range from 22% to 74%, whereas it is only 4% to 5% for the general population. Furthermore, individuals with Lynch syndrome are often diagnosed with these cancers at a much younger age than those without the condition.
The syndrome can also be associated with other Lynch-associated cancers. For instance, brain cancer can occur in individuals with Lynch syndrome, and it has been observed in younger family members. Ovarian cancer is another significant concern, and its diagnosis can be particularly challenging due to the lack of reliable screening tests. Many women are not diagnosed with ovarian cancer until it has already spread, impacting survival rates. For example, only about 50% of people diagnosed with ovarian cancer live for 5 years or longer after their diagnosis.
The symptoms of cancers associated with Lynch syndrome can vary depending on the type and location of the cancer. However, some common signs and symptoms to be aware of include:
It is crucial to note that many of these symptoms can be caused by less serious conditions. However, if you experience persistent or concerning symptoms, it is important to seek medical attention.
Lynch syndrome is caused by inherited mutations in specific DNA mismatch repair (MMR) genes. The most commonly affected genes are:
When a person inherits a mutation in one of these genes, their body's ability to repair DNA errors is compromised. This leads to a buildup of mutations in other genes, increasing the likelihood of cells becoming cancerous. If a parent has Lynch syndrome, each child has a 50% chance of inheriting the mutated gene. If a child does not inherit the mutation, they cannot pass Lynch syndrome on to their own children.
Diagnosing Lynch syndrome typically involves a combination of medical history, family history, and genetic testing.
It is important for individuals with a suspected family history of Lynch syndrome to undergo genetic counseling to understand the implications of testing and to discuss the results with a genetic counselor or medical professional.
There is no cure for Lynch syndrome itself, but the focus of management is on early detection and prevention of cancers. This involves a rigorous surveillance program tailored to the individual's specific gene mutation and cancer risks.
Treatment for any cancer diagnosed in an individual with Lynch syndrome follows standard protocols for that specific cancer, but the underlying genetic predisposition means that ongoing surveillance is critical.
While Lynch syndrome is an inherited condition and cannot be prevented, its impact can be significantly mitigated through proactive management and lifestyle choices:
It is essential to consult a doctor if you have a known family history of Lynch syndrome or any of the associated cancers, especially if they occurred at a young age. You should also seek medical advice if you experience any persistent or concerning symptoms that could indicate cancer, such as:
Early detection and proactive management are key to improving outcomes for individuals with Lynch syndrome. Discussing your concerns and family history with your healthcare provider is the most important step in understanding and managing your risk.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026